personalized glp-1 Obesity care isn't one-drug-fits-all. ​ Obesity management is evolving beyond medications. ​ This session explores approaches that improve outcomes across diverse patient populations. ​ Learn how non- GLP-1 therapies can support One size fails all? The

The good news is that people with diabetes still have other medicines they can take instead of Ozempic, including several in the same family of medicines as semaglutide, Tchang notes

Aromatase inhibitors, a common class of breast cancer medication, seem to limit the effectiveness of GLP-1 drugs, perhaps due to their anti-estrogen effects

At 52 weeks, participants who switched from Wegovy to oral orforglipron experienced an average weight regain of only 0.9 kg

15% in trials but semaglutide has a longer safety record and is often easier to get covered

The offer covers plan fees - not medication manufacturing costs, because patient-specific compounded medication can't be returned under US pharmacy law

doi:10.1016/j.metabol.2008.01.013 Zhang L, Wu X, Yang R, et al